NS Pharma’s Viltepso Fails Confirmatory Phase III Trial for Duchenne Muscular Dystrophy Treatment

Viltepso, NS Pharma, Duchenne muscular dystrophy, RACER53 study, viltolarsen, FDA approval, confirmatory trial, phase III trial, DMD treatment

FDA Approves Apple Watch’s Afib-Tracking App for Clinical Research

Apple Watch, afib-tracking app, FDA certification, clinical studies, heart health, medical technology, wearable devices, digital health.